Related coverage linked through entity extraction aliases.
Jun 04, 2026
Two studies report on thoracic radiotherapy for lung cancer: a phase III trial found adding radiotherapy to chemoimmunotherapy did not improve survival in extensive-stage small cell lung cancer, while a retrospective review showed high local control rates with single-fraction 28 Gy stereotactic body radiotherapy.
May 16, 2026
FDA approves Genentech's Tecentriq as first ctDNA-guided adjuvant therapy for muscle-invasive bladder cancer, and Venclexta plus acalabrutinib as first all-oral fixed-duration regimen for CLL.
Apr 03, 2026
The ASCENT-04 trial shows Trodelvy plus Keytruda extends progression-free survival by 3.4 months in PD-L1-positive metastatic triple-negative breast cancer. Meanwhile, the ToPCourT trial investigates trilaciclib combined with pembrolizumab and chemotherapy for advanced TNBC. These developments signal evolving treatment approaches for this aggressive breast cancer subtype.
Mar 13, 2026
Meta-analysis of 23 trials finds neoadjuvant chemoimmunotherapy achieved 66% major pathologic response in head and neck cancer patients compared to 18% for dual-agent and 6% for single-agent immunotherapy, though survival impact remains unclear.
Feb 20, 2026
The FDA has approved the combination of Venclexta (venetoclax) plus acalabrutinib as the first all-oral, fixed-duration regimen for previously untreated adults with chronic lymphocytic leukemia, based on Phase III AMPLIFY study results.
